Loading the company…
Loading the company…
Families: Cholecystectomy & appendectomy.
All companies · Product and company coverage
In the last ten years FDA made 0 decisions for Cytyc Surgical Products (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family. The latest was on 2005-05-16.
| Family | Decisions on record |
|---|---|
| Cholecystectomy & appendectomy | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2005-05-16 | 510(k) | K050650 | NOVACYTE MICROENDOSCOPE AND ACCESSORIES, MODELS NC1000;NCAM1000 |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Cytyc Surgical Products.
In 2025, Cytyc Surgical Products reported engagement with 68 surgeons and other clinicians in the states MedaRep covers, worth $40K in consulting, speaking, meals and travel for its device products, the most in Colorado ($9,756 to 4). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Colorado ($9,756, 4 engaged), Maryland ($7,024, 2 engaged), California ($3,596, 4 engaged), Texas ($3,223, 7 engaged), Georgia ($2,254, 2 engaged).